|
1
|
Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol 2020; 16:2089-2099. [PMID: 32938212 PMCID: PMC9437770 DOI: 10.2217/fon-2020-0426] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72% at 6 months, 40-58% at 12 months) were consistently higher/better compared with progression-free survival rates (41/31% at 6/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Murtuza Bharmal
- EMD Serono Research & Development Institute, Inc., Rockland, MA 02370, USA; a business of Merck KGaA, Darmstadt, Germany
| | - Sandra Nolte
- ICON plc, Munich, Germany/Lyon, France.,Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Berlin Institute of Health, Berlin, Germany
| | - Céleste Lebbé
- Université de Paris, INSERM U976 & Dermatology & CIC, AP-HP, Saint Louis Hospital, Paris, France
| | - Laurent Mortier
- Department of Dermatology, CARADERM and University of Lille, Inserm U1189, CHU Lille, Lille Cedex, France
| | | | - Nicola Fazio
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, IEO, IRCCS, Milan, Italy
| | | | - Sara Pusceddu
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - Jessica C Hassel
- Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Felix Kiecker
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Berlin Institute of Health, Berlin, Germany
| | | | - Marcis Bajars
- EMD Serono Research & Development Institute, Inc., Billerica, MA 01821, USA; a business of Merck KGaA, Darmstadt, Germany
| | | | - Paul Nghiem
- Division of Dermatology, University of Washington Medical Center at South Lake Union, Seattle, WA 98109, USA
| | | | | | | | - Sandra P D'Angelo
- Department of Medicine, Weill Cornell Medical College & Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| |
Collapse
|